GENMAB AS DKK1 revenue breakdown overview

GENMAB AS DKK1 revenue for the last year amounted to 16.47 B DKK, the most of which — 16.47 B DKK — came from its highest performing source at the moment, Antibody Therapeutics, the year earlier bringing 14.60 B DKK. The greatest contribution to the revenue figure was made by Denmark — last year it brought GENMAB AS DKK1 16.05 B DKK, and the year before that — 14.60 B DKK.